|Title:||Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study||Authors:||Mercader-García, Pedro
Pastor-Nieto, María A.
Gatica-Ortega, María E.
Silvestre-Salvador, Juan F.
Armario-Hita, José Carlos
Carrascosa-Carrillo, José Manuel
Gatica-Ortega, María Elena
Giménez-Arnau, Ana María
Gómez de la Fuente, Enrique
Ortiz de Frutos, Javier
Pastor-Nieto, María Antonia
Silvestre, Juan Francisco
|UNESCO Clasification:||32 Ciencias médicas
|Issue Date:||2017||Journal:||Contact Dermatitis||Abstract:||Background Corticosteroids are among the most commonly used topical drugs. Contact allergy to these exists, but can be easily missed. Corticosteroid screening markers have been included in the baseline series with the aim of detecting most of the sensitized patients. Objectives To assess the prevalence of contact allergy to topical corticosteroids in Spain and examine the usefulness of corticosteroid markers to detect contact allergy to corticosteroids. Methods In total, 3699 patients referred to 20 dermatology departments across Spain for patch testing with the baseline series, including budesonide and tixocortol pivalate, were also tested with six supplementary corticosteroids (methylprednisolone aceponate, mometasone furoate, prednicarbate, clobetasol propionate, betamethasone 17-valerate, and betamethasone 17,21-dipropionate). Additionally, 2547 (68.8%) patients were tested with hydrocortisone 17-butyrate. Results Fifty-four patients showed positive reactions to at least one of all tested corticosteroids (1.46%). Thirty-nine (1.05%) reacted to at least one of the additionally tested corticosteroids; among these, 24 of 39 (61.5%) did not react to any of the corticosteroid allergy screening markers tested. Conclusions More than half of the patients who were allergic to the additionally tested corticosteroids were not detected with the corticosteroid allergy markers. An update of the corticosteroid allergy screening markers is encouraged, with consideration of group 3 corticosteroids.||URI:||http://hdl.handle.net/10553/49131||ISSN:||0105-1873||DOI:||10.1111/cod.12874||Source:||Contact Dermatitis[ISSN 0105-1873],v. 78, p. 76-82 (Septiembre 2017)|
|Appears in Collections:||Artículos|
checked on Aug 7, 2022
checked on May 28, 2022
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.